Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Recruiting

Phase 2

Duvelisib & CC-486Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT04803201

Conditions

Angioimmunoblastic T-cell Lymphoma

Enteropathy-Associated T-Cell Lymphoma

Follicular T-Cell Lymphoma

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide

Doxorubicin

Vincristine

Prednisone

Etoposide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-02. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2025-04-02.